parkinson's%20disease%20-and-%20parkinson's%20disease%20dementia
PARKINSON'S DISEASE & PARKINSON'S DISEASE DEMENTIA

Parkinson's disease is a progressive neurodegenerative disorder that is common, age-related and chronic.

It is caused by loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain.

Onset of symptoms and progression of the disease is gradual.

Motor signs and symptoms include resting tremor, rigidity, bradykinesia and postural instability.

Parkinson's disease dementia indicates loss of intellectual functions including memory, significant deterioration in the ability to carry out day-to-day activities and changes in social behavior are often noted.

Introduction

  • Parkinson's Disease (PD) is a common, age-related, chronic, progressive disorder caused by loss or degeneration of dopaminergic neurons in the substantia nigra of the midbrain
  • Pathologic hallmark is loss of dopaminergic substantia nigra neurons with surviving neurons often containing a characteristic cytoplasmic inclusion body (Lewy body)
  • Increased prevalence & incidence rates are noted in the elderly
  • Men have higher incidence rate, with relative risk 1.5 times more than in women

Signs and Symptoms

  • Early symptoms are subtle and occur gradually

Motor signs and symptoms

  • Resting tremor
  • Rigidity
  • Bradykinesia
  • Postural instability

Nonmotor signs and symptoms

  • Autonomic (eg gastrointestinal dysfunction, urinary and sexual dysfunction, orthostatic hypotension, hyperhidrosis)
  • Sleep disorders (eg impaired sleep initiation and maintenance, rapid eye movement sleep behavior disorder and excessive daytime sleepiness)
  • Sensory (eg pain, hyposmia, visual dysfunction)
  • Neuropsychiatric (eg depression, anxiety and panic attacks, dementia, psychosis)
Editor's Recommendations
Most Read Articles
Elvira Manzano, 29 May 2018
Repeat doses of the intrathecal antisense oligonucleotide nusinersen in children with infantile-onset spinal muscular atrophy (SMA) continue to demonstrate safety, according to  early data from the phase III SHINE extension study, bringing considerable hope to the SMA community.
Audrey Abella, 29 Aug 2018
The combination of the alkylating nitrosourea compound lomustine and the monoclonal antibody bevacizumab prolonged progression-free survival (PFS) in patients with progressive glioblastoma compared with either drug alone, a meta-analysis has shown.
31 Aug 2018
New drug applications approved by US FDA as of 16 - 31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
29 Aug 2018
The risk of traumatic brain injury (TBI) is elevated in young people with attention-deficit/hyperactivity disorder (ADHD), though long-term ADHD medication can reduce this risk, a recent study has found.